InductEV is at the forefront of revolutionizing commercial fleets through the power of wireless energy. With our AI-driven solutions and innovative hardware, we are reshaping the landscape of sustainable mobility. Our commitment to a greener future is reflected in the development of cutting-edge technology that enables seamless integration, optimized performance, and reduced carbon footprint for fleet operators worldwide.\n \nInductEV's exceptional team of talented engineers, scientists, operators, and innovators is dedicated to delivering highly efficient and lightning-fast wireless power solutions. Our technology is tailored for fleets of all sizes located around the world. Supported by prominent investors and government agencies, InductEV is poised for exponential growth as we lead the charge in electrifying logistics, transportation, ports and transit.\n \nOur mission is to facilitate the success of businesses and the planet by driving the widespread adoption of wireless energy. With a firm commitment to sustainability and innovation, InductEV is dedicated to creating a thriving future where wireless power revolutionizes industries and positively impacts lives.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), and hepatitis C virus and human immunodeficiency virus vaccines. It is also advancing preclinical research and clinical development for a seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.